肾康注射液联合缬沙坦治疗糖尿病肾脏病的疗效观察  

Curative effectiveness of Shenkang injection combined with valsartan for diabetic kidney disease

作　　者：周西豫[1] 谢飞[1] 闫鲲[1] 郭兴福[1] 白咏梅[1] 

机构地区：[1]武警陕西总队医院肾脏科,西安710054

出　　处：《临床肾脏病杂志》2012年第7期331-333,共3页Journal Of Clinical Nephrology

摘　　要：目的探讨肾康注射液联合缬沙坦对慢性肾脏病（CKD）〉3期糖尿病。肾脏病（diabetickidneydisease，DKD）患者的治疗效果。方法80例DKD患者随机分为缬沙坦组（对照组）和缬沙坦联合肾康注射液组（治疗组），每组40例。2组均行常规治疗2个月，观察2组治疗前后的24h尿蛋白定量、血肌酐（SCr）、尿素氮（BUN）、血浆白蛋白（Alb）和体质量指数（BMI）等指标的变化。结果治疗组24h尿蛋白定量、SCr、BUN与治疗前比较均有显著改善（P〈0．01），且显著优于对照组（P〈0．05）；2组Alb和BMI较治疗前有统计学差异（P〈0．05），但组间比较无统计学差异（P〉0．05）。结论肾康注射液联合缬沙坦治疗CKD〉3期DKD患者能够显著改善肾功能，可以延缓或逆转早期DKD进展。Objective To explore the curative effectiveness of Shenkang injection combined with valsartan in the treatment of early diabetic nephropathy（CKD 3）. Methods Eighty patients with CKD 3 were randomly divided into two groups： group A（n = 40） was treated with valsartan （80 rag, once daily） on the basis of routine treatment for 8 weeks; group B（n = 40） was treated with valsartan as the same in group A and Shenkang injection （once daily） on the basis of routine treatment. The changes of serum creatinine （SCr）, blood urea nitrogen（BUN）, 24-h urine albumin quantity, albumin （Alb） and body mass index（BMI） in two groups were observed before and after treatment. Results Compared with pre-treatment, SCr, Alb, BUN and 24-h urine albumin quantity in group B were improved signifieantly（P〈0. 01）, and there was significant difference between the two groups（P〈0. 05）. There was a statistically significant difference in Alb and BMI before and after treatment（P〈0. 05）, but there was no significant difference between the two groups （P〉0. 05）. Conclusions Shenkang injection combined with valsartan for the treatment of CKD 3 can improve renal function and significantly delay the progression of diabetic nephropathy.

关 键 词：糖尿病肾脏病 血管紧张素转换酶抑制剂 中草药 

分 类 号：R285.5[医药卫生—中药学]